Human immunodeficiency virus type 1 Vpr increases hepatitis C virus RNA replication in cell culture

Virus Research

Volumn 184, Issue , 2014, Pages 93-102

  Deng, Amei ^a   Chen, Chao ^a   Ishizaka, Yukihito ^b   Chen, Xinwen ^a   Sun, Binlian ^a   Yang, Rongge ^a  

^a WUHAN INSTITUTE OF VIROLOGY   (China)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Coinfection; Hepatitis C virus; Human immunodeficiency virus; RNA replication; Vpr

Indexed keywords

CORE PROTEIN; GAG PROTEIN; MONTIRELIN; NONSTRUCTURAL PROTEIN 4B; PEGINTERFERON; VIRUS RNA; VPR PROTEIN;

ANTIVIRAL THERAPY; ARTICLE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA REPLICATION; VIRUS ENTRY; VIRUS LOAD; VIRUS PARTICLE; CELL LINE; EPITHELIUM CELL; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; LIVER CELL; METABOLISM; PHYSIOLOGY; VIROLOGY; VIRUS CULTURE; VIRUS REPLICATION;

CELL LINE; EPITHELIAL CELLS; HEPACIVIRUS; HEPATOCYTES; HUMANS; VIRUS CULTIVATION; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84898621765     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2014.02.017     Document Type: Article

References (45)

1. Algeciras-Schimnich A., Vlahakis S.R., Villasis-Keever A., Gomez T., Heppelmann C.J., Bou G., Paya C.V. CCR5 mediates Fas- and caspase-8 dependent apoptosis of both uninfected and HIV infected primary human CD4T cells. AIDS 2002, 16:1467-1478.
2. Chen C., Pan D., Deng A.M., Huang F., Sun B.L., Yang R.G. DNA methyltransferases 1 and 3B are required for hepatitis C virus infection in cell culture. Virology 2013, 441:57-65.
3. Chen C., Qiu H., Gong J., Liu Q., Xiao H., Chen X.W., Sun B.L., Yang R.G. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Archives of Virology 2012, 157:1301-1312.
4. Cohen E.A., Dehni G., Sodroski J.G., Haseltine W.A. Human immunodeficiency virus vpr product is a virion-associated regulatory protein. Journal of Virology 1990, 64:3097-3099.
5. Connor R.I., Chen B.K., Choe S., Landau N.R. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 1995, 206:935-944.
6. Di Martino V., Rufat P., Boyer N., Renard P., Degos F., Martinot-Peignoux M., Matheron S., Le Moing V., Vachon F., Degott C., Valla D., Marcellin P. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001, 34:1193-1199.
7. Eyster M.E., Fried M.W., Di Bisceglie A.M., Goedert J.J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84:1020-1023.
8. Felzien L.K., Woffendin C., Hottiger M.O., Subbramanian R.A., Cohen E.A., Nabel G.J. HIV transcriptional activation by the accessory protein, VPR, is mediated by the p300 co-activator. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:5281-5286.
9. Ferrucci A., Nonnemacher M.R., Cohen E.A., Wigdahl B. Extracellular human immunodeficiency virus type 1 viral protein R causes reductions in astrocytic ATP and glutathione levels compromising the antioxidant reservoir. Virus Research 2012, 167:358-369.
10. Ferrucci A., Nonnemacher M.R., Wigdahl B. Extracellular HIV-1 viral protein R affects astrocytic glyceraldehyde 3-phosphate dehydrogenase activity and neuronal survival. Journal of Neurovirology 2013, 19:239-253.
11. Han Q., Xu C., Wu C., Zhu W., Yang R., Chen X. Compensatory mutations in NS3 and NS5A proteins enhance the virus production capability of hepatitis C reporter virus. Virus Research 2009, 145:63-73.
12. He J., Choe S., Walker R., Di Marzio P., Morgan D.O., Landau N.R. Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. Journal of Virology 1995, 69:6705-6711.
13. Heinzinger N.K., Bukinsky M.I., Haggerty S.A., Ragland A.M., Kewalramani V., Lee M.A., Gendelman H.E., Ratner L., Stevenson M., Emerman M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:7311-7315.
14. Hoshino S., Sun B., Konishi M., Shimura M., Segawa T., Hagiwara Y., Koyanagi Y., Iwamoto A., Mimaya J., Terunuma H., Kano S., Ishizaka Y. Vpr in plasma of HIV type 1-positive patients is correlated with the HIV type 1 RNA titers. AIDS Research and Human Retroviruses 2007, 23:391-397.
15. Iijima K., Okudaira N., Tamura M., Doi A., Saito Y., Shimura M., Goto M., Matsunaga A., Kawamura Y.I., Otsubo T., Dohi T., Hoshino S., Kano S., Hagiwara S., Tanuma J., Gatanaga H., Baba M., Iguchi T., Yanagita M., Oka S., Okamura T., Ishizaka Y. Viral protein R of human immunodeficiency virus type-1 induces retrotransposition of long interspersed element-1. Retrovirology 2013, 10:83.
16. Kato T., Date T., Miyamoto M., Sugiyama M., Tanaka Y., Orito E., Ohno T., Sugihara K., Hasegawa I., Fujiwara K., Ito K., Ozasa A., Mizokami M., Wakita T. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system. Journal of Clinical Microbiology 2005, 43:5679-5684.
17. Kato T., Date T., Murayama A., Morikawa K., Akazawa D., Wakita T. Cell culture and infection system for hepatitis C virus. Nature Protocols 2006, 1:2334-2339.
18. Kino T., Gragerov A., Slobodskaya O., Tsopanomichalou M., Chrousos G.P., Pavlakis G.N. Human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. Journal of Virology 2002, 76:9724-9734.
19. Levy D.N., Refaeli Y., MacGregor R.R., Weiner D.B. Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America 1994, 91:10873-10877.
20. Levy D.N., Refaeli Y., Weiner D.B. Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. Journal of Virology 1995, 69:1243-1252.
21. Liu H.M., Aizaki H., Machida K., Ou J.H., Lai M.M. Hepatitis C virus translation preferentially depends on active RNA replication. PLoS ONE 2012, 7:e43600.
22. Martin-Carbonero L., Soriano V., Valencia E., Garcia-Samaniego J., Lopez M., Gonzalez-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Research and Human Retroviruses 2001, 17:1467-1471.
23. Monga H.K., Rodriguez-Barradas M.C., Breaux K., Khattak K., Troisi C.L., Velez M., Yoffe B. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clinical Infectious Diseases 2001, 33:240-247.
24. Qu J., Yang Z., Zhang Q., Liu W., Li Y., Ding Q., Liu F., Liu Y., Pan Z., He B., Zhu Y., Wu J. Human immunodeficiency virus-1 Rev protein activates hepatitis C virus gene expression by directly targeting the HCV 5'-untranslated region. FEBS Letters 2011, 585:4002-4009.
25. Qu J., Zhang Q., Li Y., Liu W., Chen L., Zhu Y., Wu J. The Tat protein of human immunodeficiency virus-1 enhances hepatitis C virus replication through interferon gamma-inducible protein-10. BMC Immunology 2012, 13:15.
26. Re F., Braaten D., Franke E.K., Luban J. Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. Journal of Virology 1995, 69:6859-6864.
27. Rey D., Fritsch S., Schmitt C., Meyer P., Lang J.M., Stoll-Keller F. Quantitation of hepatitis C virus RNA in saliva and serum of patients coinfected with HCV and human immunodeficiency virus. Journal of Medical Virology 2001, 63:117-119.
28. Rey D., Schmitt M.P., Hess-Kempf G., Krantz V., Partisani M., Bernard-Henry C., Lang J.M. Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results. Pathologie-Biologie 2001, 49:559-566.
29. Rockstroh J.K., Spengler U., Sudhop T., Ewig S., Theisen A., Hammerstein U., Bierhoff E., Fischer H.P., Oldenburg J., Brackmann H.H., Sauerbruch T. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. The American Journal of Gastroenterology 1996, 91:2563-2568.
30. Rotman Y., Liang T.J. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. Journal of Virology 2009, 83:7366-7374.
31. Sherman K.E., Peters M., Koziel M.J. HIV and liver disease forum: conference proceedings. Hepatology 2007, 45:1566-1577.
32. Sherman M.P., Schubert U., Williams S.A., de Noronha C.M., Kreisberg J.F., Henklein P., Greene W.C. HIV-1 Vpr displays natural protein-transducing properties: implications for viral pathogenesis. Virology 2002, 302:95-105.
33. Soriano V., Sulkowski M., Bergin C., Hatzakis A., Cacoub P., Katlama C., Cargnel A., Mauss S., Dieterich D., Moreno S., Ferrari C., Poynard T., Rockstroh J. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16:813-828.
34. Stewart S.A., Poon B., Jowett J.B., Chen I.S. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. Journal of Virology 1997, 71:5579-5592.
35. Sulkowski M.S., Thomas D.L. Hepatitis C in the HIV-infected person. Annals of Internal Medicine 2003, 138:197-207.
36. Sulkowski M.S., Thomas D.L., Chaisson R.E., Moore R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. Journal of the American Medical Association 2000, 283:74-80.
37. Tanaka M., Sun B., Tezuka K., Fujisawa J., Tanaka Y., Hoshino H., Miwa M. Neuraminidase enhances the initial steps of human T-cell leukemia virus type 1 replication. Microbes and Infection/Institut Pasteur 2010, 12:119-125.
38. Telfer P.T., Brown D., Devereux H., Lee C.A., DuSheiko G.M. HCV RNA levels and HIV infection: evidence for a viral interaction in haemophilic patients. British Journal of Haematology 1994, 88:397-399.
39. Torriani F.J., Ribeiro R.M., Gilbert T.L., Schrenk U.M., Clauson M., Pacheco D.M., Perelson A.S. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. The Journal of Infectious Diseases 2003, 188:1498-1507.
40. Tristem M., Marshall C., Karpas A., Hill F. Evolution of the primate lentiviruses: evidence from vpx and vpr. The EMBO Journal 1992, 11:3405-3412.
41. Vlahakis S.R., Villasis-Keever A., Gomez T.S., Bren G.D., Paya C.V. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. The Journal of Infectious Diseases 2003, 188:1455-1460.
42. von Hahn T., Rice C.M. Hepatitis C virus entry. The Journal of Biological Chemistry 2008, 283:3689-3693.
43. Wen X., Casey Klockow L., Nekorchuk M., Sharifi H.J., de Noronha C.M. The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover. PLoS ONE 2012, 7:e30939.
44. Zhang C., Yang R., Xia X., Qin S., Dai J., Zhang Z., Peng Z., Wei T., Liu H., Pu D., Luo J., Takebe Y., Ben K. High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. Journal of Acquired Immune Deficiency Syndromes 2002, 29:191-196.
45. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:9294-9299.